Tourmaline Bio to Present at the Jefferies Global Healthcare Conference
23 mai 2024 07h10 HE
|
Tourmaline Bio, Inc.
Sandeep Kulkarni, CEO of Tourmaline Bio, is expected to participate in the Jefferies Global Healthcare Conference in New York on June 9, 2024
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
16 mai 2024 07h00 HE
|
Tourmaline Bio, Inc.
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
13 mai 2024 07h00 HE
|
Tourmaline Bio, Inc.
Tourmaline Bio announces financial results and business highlights for the first quarter ended March 31, 2024
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
19 mars 2024 07h00 HE
|
Tourmaline Bio, Inc.
– Initiated pivotal spiriTED Phase 2b trial in Thyroid Eye Disease (TED) in 2023 and expanded TED clinical development plan, including accelerating the planned initiation of a pivotal Phase 3 trial...
Tourmaline Bio to Present at Upcoming Investor Conferences
27 févr. 2024 07h30 HE
|
Tourmaline Bio, Inc.
NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve...
Tourmaline Bio to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
01 févr. 2024 08h00 HE
|
Tourmaline Bio, Inc.
NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve...
Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
29 janv. 2024 16h01 HE
|
Tourmaline Bio, Inc.
NEW YORK, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically...
Tourmaline Bio Announces Pricing of Public Offering of Common Stock
25 janv. 2024 07h00 HE
|
Tourmaline Bio, Inc.
NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically...
Tourmaline Bio Announces Proposed Public Offering of Common Stock
24 janv. 2024 16h05 HE
|
Tourmaline Bio, Inc.
NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically...
Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)
08 janv. 2024 07h00 HE
|
Tourmaline Bio, Inc.
Tourmaline plans to accelerate the initiation of a pivotal Phase 3 trial in 2024 evaluating subcutaneous TOUR006 every 8 weeks as first-line treatment for TED, with topline data expected in 2026 ...